NASDAQ:EYEG - Eyegate Pharmaceuticals Stock Price, Price Target & More

Eyegate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) released its quarterly earnings results on Friday, May, 11th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.10. The specialty pharmaceutical company earned $1.10 million during the quarter, compared to analysts' expectations of $0.49 million. Eyegate Pharmaceuticals had a negative return on equity of 653.57% and a negative net margin of 2,480.28%. View Eyegate Pharmaceuticals' Earnings History.

1 brokerages have issued 1-year price objectives for Eyegate Pharmaceuticals' stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Eyegate Pharmaceuticals' share price to reach $3.00 in the next twelve months. View Analyst Ratings for Eyegate Pharmaceuticals.

Eyegate Pharmaceuticals saw a decline in short interest in May. As of May 31st, there was short interest totalling 537,432 shares, a decline of 27.5% from the May 15th total of 741,705 shares. Based on an average daily trading volume, of 610,854 shares, the short-interest ratio is presently 0.9 days. Currently, 1.5% of the shares of the stock are short sold. View Eyegate Pharmaceuticals' Current Options Chain.

Some companies that are related to Eyegate Pharmaceuticals include KemPharm (KMPH), Cumberland Pharmaceuticals (CPIX), DiaMedica Therapeutics (DMCAF), Kalvista Pharmaceuticals (KALV), Trillium Therapeutics (TRIL), Gemphire Therapeutics (GEMP), Advaxis (ADXS), Medicure Inc. Common Stock (MCUJF), Aileron Therapeutics (ALRN), Axsome Therapeutics (AXSM), Evofem Biosciences (EVFM), Checkpoint Therapeutics (CKPT), VIVUS (VVUS), Cardiome Pharma (CRME) and Versartis (VSAR).

(EYEG) raised $5 million in an initial public offering on Friday, February 13th 2015. The company issued 800,000 shares at a price of $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.

Press coverage about EYEG stock has trended somewhat negative this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eyegate Pharmaceuticals earned a media sentiment score of -0.18 on Accern's scale. They also assigned news coverage about the specialty pharmaceutical company an impact score of 46.38 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Eyegate Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include ARMISTICE CAPITAL, LLC (40.20%), ARMISTICE CAPITAL, LLC (50.80%) and ARMISTICE CAPITAL, LLC (4.99%). Company insiders that own Eyegate Pharmaceuticals stock include Armistice Capital Master Fund, Morton Goldberg, Sarah Romano and Stephen From. View Institutional Ownership Trends for Eyegate Pharmaceuticals.

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EYEG stock can currently be purchased for approximately $0.56.

Eyegate Pharmaceuticals has a market capitalization of $23.78 million and generates $410,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,210,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Eyegate Pharmaceuticals employs 17 workers across the globe.

Eyegate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at 781-788-8869.